# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Satchel Paige (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML047-SYN
- Date: 2026-07-14
- Fictional facility: St. Posthumous Health Center
- Fictional author: Delphine Whitaker-Osei, MD
- Calendar frame: modern shifted

## What we are working on

- Breathless on stairs and on walks he used to take easily **S**
- He wants straight answers and his own numbers, and to be treated the same as anyone else **S**
- He wants to keep fishing and speaking to young people **S**

## Your goals

- Find the cause of the breathlessness. Target: 2026-07-28. Recorded outcome: COPD confirmed by spirometry (post-bronchodilator FEV1/FVC 0.58); heart failure unlikely (NT-proBNP 92, normal ECG); alpha-1 antitrypsin normal. **S**
- Walk farther with less breathlessness. Target: 2026-10-27. Recorded outcome: Six-minute walk 360 to 425 m after rehabilitation; CAT 18 to 11. **S**
- Fewer and milder flare-ups, treated early. Target: 2027-07-14. Recorded outcome: One moderate exacerbation treated at home within a day of starting, using the action plan; no hospital stay. **S**
- LDL below 100 mg/dL. Target: 2026-09-08. Recorded outcome: LDL 148 to 86 mg/dL on atorvastatin 20 mg. **S**
- Vaccines up to date. Target: 2026-10-06. Recorded outcome: PCV20 and Tdap at intake; influenza, RSV, COVID-19 and the first zoster dose at the wellness visit. **S**

## What we agreed to do

- Breathlessness work-up at intake: symptoms with the CAT and mMRC, exacerbation history over the past year, smoking history and examination; blood count with eosinophils, alpha-1 antitrypsin once, kidney function, HbA1c, lipids, NT-proBNP and a 12-lead ECG; resting oxygen saturation read with care in darker skin. Guideline: Global Strategy for the Prevention, Diagnosis and Management of COPD: 2025 Report (2025); Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement (2023); CMID: Clinical Monitoring Intelligence Database, COPD and hyperlipidemia monographs (2026) **S**
- Pulmonology consultation to confirm the diagnosis with spirometry, interpret it with race-neutral equations, and advise on treatment, oxygen and rehabilitation. Guideline: Global Strategy for the Prevention, Diagnosis and Management of COPD: 2025 Report (2025); Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement (2023) **S**
- Albuterol with a spacer as needed for breathlessness, with technique checked at the visit. Guideline: Global Strategy for the Prevention, Diagnosis and Management of COPD: 2025 Report (2025) **S**
- Maintenance therapy for GOLD group B: a LAMA with a LABA (umeclidinium with vilanterol) once daily; no inhaled corticosteroid with eosinophils below 0.10 x 10^3/uL and no exacerbations; inhaler technique and inspiratory effort checked at every visit; treatment reviewed at each follow-up for symptoms and exacerbations. Guideline: Global Strategy for the Prevention, Diagnosis and Management of COPD: 2025 Report (2025); CMID: Clinical Monitoring Intelligence Database, COPD and hyperlipidemia monographs (2026) **S**
- Pulmonary rehabilitation: twice a week for about ten weeks, with six-minute walks at entry and exit, then a home exercise program. Guideline: CMID: Clinical Monitoring Intelligence Database, COPD and hyperlipidemia monographs (2026); Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline (2023) **S**
- Oxygen: room-air arterial blood gas and six-minute walk oximetry; long-term oxygen only if resting PaO2 is 55 mm Hg or less (60 with cor pulmonale or polycythemia), confirmed twice; no long-term or ambulatory oxygen for moderate desaturation. Guideline: Home Oxygen Therapy for Adults with Chronic Lung Disease: An Official American Thoracic Society Clinical Practice Guideline (2020); A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation (LOTT) (2016); Racial Bias in Pulse Oximetry Measurement (2020) **S**
- Lung cancer screening: yearly low-dose CT at 50 to 80 with 20 or more pack-years, after shared decision-making, while he has quit within fifteen years and remains fit for treatment. Guideline: CMID: Clinical Monitoring Intelligence Database, COPD and hyperlipidemia monographs (2026); Lung Cancer: Screening (2021) **S**
- Cardiovascular risk: moderate-intensity atorvastatin by shared decision, with a lipid panel at about eight weeks; blood pressure at each visit; ECG reviewed after any exacerbation. Guideline: Global Strategy for the Prevention, Diagnosis and Management of COPD: 2025 Report (2025); Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication (2022) **S**
- Vaccines: PCV20 and Tdap now; influenza, RSV and COVID-19 in the autumn; recombinant zoster. Guideline: Global Strategy for the Prevention, Diagnosis and Management of COPD: 2025 Report (2025); Adult Immunization Schedule by Age (2026) **S**
- COPD action plan, spoken and written: what to do on a good day, when symptoms worsen (reliever, call the clinic the same day), and when to call 911; staying smoke-free. Guideline: Global Strategy for the Prevention, Diagnosis and Management of COPD: 2025 Report (2025) **S**

## Follow-up

- 2026-07-14: Establishing primary care for two years of breathlessness on exertion and a morning cough: history, examination, blood tests including alpha-1 antitrypsin and eosinophils, ECG, NT-proBNP, cardiovascular risk, vaccines, a reliever inhaler and a pulmonology consultation **S**
- 2026-07-28: Two-week review on the day of the pulmonology consultation: spirometry with race-neutral interpretation, blood gas, six-minute walk, GOLD group and first maintenance inhaler, inhaler technique, pulmonary rehabilitation and lung cancer screening **S**
- 2026-09-08: Eight-week review: symptoms on the new inhaler, technique, rehabilitation, the screening CT and the lipid response **S**
- 2026-10-06: Subsequent annual wellness visit **S**
- 2026-10-27: Fifteen-week review after an exacerbation and pulmonary rehabilitation: symptoms, exacerbation history, GOLD group, oxygen, the action plan and the plan ahead **S**

This teaching document does not replace care from a qualified clinician.
